Nektar Therapeutics (NKTR)

Published 2026-03-23 • by yetanothervalueblog

BiotechnologyBiotechPipelineAutoimmuneCatalysts
Original Post ↗SEC:
[All][10-K][10-Q]
Market Intel:
Yahoo Finance 📊TradingView 📈Koyfin 🎯

Thesis Summary

Nektar ($NKTR) represents a high-optionality biotech investment with its key autoimmune drug candidate (rezpegaldesleukin) entering critical phase 2 trial reads.

Quantitative Overlay

Detailed Deep Dive

Nektar Therapeutics ($NKTR) is a clinical-stage biotechnology company focused on developing immunotherapies. In collaboration with Eli Lilly (and subsequently regaining full rights), Nektar is developing rezpegaldesleukin (REZPEG) for autoimmune diseases. The investment thesis focuses on the substantial valuation discount relative to the potential market for REZPEG and upcoming phase 2 data readouts.